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a  b  s  t  r  a  c  t
Long-term  use  of  benzodiazepine-type  drugs  may  lead  to physical  dependence,  manifested  by  withdrawal
syndrome  after  abrupt  cessation  of treatment.  The aim  of the  present  study  was  to  investigate  the inﬂu-
ence  of  duration  of  treatment,  as well  as  the  role of 1-containing  GABAA receptors,  in development  of
physical  dependence  to diazepam,  assessed  through  the level  of  anxiety  and  susceptibility  to  pentylenete-
trazole  (PTZ)-induced  seizures,  24 h  after  withdrawal  from  protracted  treatment  in  rats.  Withdrawal  of
2  mg/kg  diazepam  after  28,  but not  after  14  or 21  days  of  administration  led to  an  anxiety-like  behav-
ior  in  the  elevated  plus  maze.  Antagonism  of the  diazepam  effects  at 1-containing  GABAA receptors,
achieved  by  daily  administration  of  the  neutral  modulator  CCt  (5 mg/kg),  did  not affect  the  anxiety  level
during  withdrawal.  An  increased  susceptibility  to  PTZ-induced  seizures  was  observed  during  diazepam
withdrawal  after 21  and  28  days  of  treatment.  Daily  co-administration  of  CCt further  decreased  the
PTZ-seizure  threshold  after  21  days  of  treatment,  whilst  it prevented  the  diazepam  withdrawal-elicited
decrease  of the  PTZ  threshold  after 28 days  of treatment.  In conclusion,  the  current  study  suggests  that
the  role  of 1-containing  GABAA receptors  in mediating  the  development  of  physical  dependence  may
vary  based  on  the  effect  being  studied  and  duration  of  protracted  treatment.  Moreover,  the  present  data
supports  previous  ﬁndings  that the  lack  of  activity  at 1-containing  GABAA receptors  is not  sufﬁcient  to
eliminate  physical  dependence  liability  of  ligands  of  the  benzodiazepine  type.
©  2014 Elsevier  Inc.  All  rights  reserved.. Introduction
Benzodiazepines were introduced into clinical practice more
han 50 years ago and are still commonly prescribed drugs due
o their anxiolytic, sedative-hypnotic, anticonvulsant and muscle
elaxant effects. These drugs bind to a speciﬁc allosteric binding site
t GABAA receptors and modulate activity of GABAA receptors that
ontain either of four  subunits: 1, 2, 3, or 5, in combination
ith the 2 subunit (Smith and Rudolph, 2012). However, despitelinical beneﬁts of acute therapy, prolonged use of benzodiazepines
s hampered by the development of tolerance to some of their
ehavioral effects, as well as physical dependence liability (Bateson,
∗ Corresponding author. Tel.: +381 11 3951280; fax: +381 11 3972840.
E-mail address: miroslav@pharmacy.bg.ac.rs (M.M.  Savic´).
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361-9230/© 2014 Elsevier Inc. All rights reserved.2002). Physical dependence is a state of adaptation manifested
by withdrawal syndrome: time-limited biochemical, physiologi-
cal and behavioral disruptions upon termination of a regimen of
chronic drug administration (Carter and Grifﬁths, 2009). Benzodi-
azepine withdrawal signs and symptoms range from mild to severe
and may  include anxiety, insomnia, irritability, headache, gastroin-
testinal disturbance, depersonalization and seizures (Grifﬁths and
Weerts, 1997).
In the laboratory conditions, physical dependence to a
benzodiazepine-type drug is assessed by the occurrence of the
characteristic withdrawal signs upon cessation of the drug after
protracted treatment (Licata and Rowlett, 2008). An anxiety-like
behavior developed after benzodiazepine withdrawal in rats is
commonly seen in the elevated plus maze test 12–96 h upon abrupt
drug discontinuation (Izzo et al., 2001; dos Santos et al., 2010).
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enzodiazepine partial inverse agonist (FG 7142), full inverse ago-
ist (DMCM) or GABAA receptor antagonist – pentylenetetrazole
PTZ) in diazepam withdrawn animals has been shown to reﬂect
he withdrawal hyperexcitability (Izzo et al., 2001; Mori et al.,
012; Tsuda et al., 1998). Although assessment of benzodiazepine
ependence is conceptually simple, interpretation and comparison
f the results from different laboratories can be complicated due to
ifferences in duration of treatment, frequency of administration,
he dose taken, the route of administration, time over which with-
rawal syndrome will be observed, and choice of the behavioral
esponse assessed (Ator and Grifﬁths, 2003; Moser et al., 2011).
The neurobiological mechanisms underlying dependence on
enzodiazepine-type drugs are not well characterized yet. How-
ver, it is generally accepted that multiple adaptive mechanisms
re involved in the different components of BZ dependence. In
ddition to the regionally and temporally selective changes at
he level of GABAA receptor function (Pratt et al., 1998; Wright
t al., 2014), the role of adaptive processes at excitatory synapses
as been also indicated (Allison and Pratt, 2006). Close neuro-
natomical relationships between glutamatergic and GABAergic
eurons and the pivotal role of glutamatergic neurotransmission
n mediating various forms of synaptic plasticity make glutamate
 key candidate for changes in excitatory mechanisms and ben-
odiazepine dependence (Stephens, 1995; reviewed in Allison and
ratt, 2003). It has been shown that even a single injection of ben-
odiazepines is sufﬁcient to induce synaptic plasticity at excitatory
lutamatergic synapses, and such an initial adaptive step depended
n the activation of 1-containing GABAA receptors expressed on
earby interneurons (Heikkinen et al., 2009; Tan et al., 2010).
he potentiation of 1-containing GABAA receptors, expressed on
nterneurons, selectively inhibits GABA neurons and modulates
lutamatergic neurotransmission, leading to the effect similar to
hat obtained with allopregnanolone and activation of presynaptic
ABAA receptors (Iwata et al., 2013).
In pharmacological terms, studies on the contribution of
peciﬁc subtypes of GABAA receptors in processes underlying
nitiation, development and manifestation of dependence to ben-
odiazepines are of particular interest. In this regard, it has been
ecently proposed that 1-containing GABAA receptors play an
mportant role in behaviors that are related to the initiation of
hysical dependence, following single administration of conven-
ional benzodiazepines in squirrel monkeys (Fischer et al., 2013).
dditionally, using different subtype selective positive allosteric
odulators with reduced efﬁcacy, Ator et al. (2010) and Mirza
nd Nielsen (2006) have shown that lack of efﬁcacy at the 1-
ontaining GABAA receptors, probably coupled with the reduced
fﬁcacy at the 2- and 3-containing receptors, led to reduced
hysical dependence liability in baboons and mice, respectively.
oreover, a recent study from our group has demonstrated the
igniﬁcant involvement of 1-containing GABAA receptors in the
anifestation of increased anxiety during withdrawal (Divljakovic´
t al., 2013).
In the present study, we investigated the inﬂuence of duration
f treatment, as well as the role of 1-containing GABAA recep-
ors, in development of physical dependence to diazepam, assessed
hrough the level of anxiety and susceptibility to PTZ-induced
eizures, 24 h after withdrawal from diazepam protracted treat-
ent in rats. To accomplish this, we used an innovative approach
n the dependence research ﬁeld. The 1-selective neutral modu-
ator CCt (Huang et al., 1999) was protractedly co-administered
ith diazepam for 14, 21 or 28 days, in order to selectively block
he diazepam’s effects mediated through this GABAA receptor sub-
ype. We  aimed to compare the consequences of withdrawal from
iazepam itself with those effects of this standard benzodiazepine
igand exerted through 2/3- or 5-, but not 1-containing GABAA
eceptors.h Bulletin 104 (2014) 1–6
2. Materials and methods
2.1. Animals
Experiments were carried out on ninety male Wistar rats (Mili-
tary Farm, Belgrade, Serbia), weighing 180–220 g at the beginning
of experiment. All procedures in the study conformed to EEC Direc-
tive 86/609 and were approved by the Ethical Committee on Animal
Experimentation of the Faculty of Pharmacy in Belgrade. The rats
were housed in plastic cages, ﬁve animals per cage, on a 12 h
light/dark cycle (light on at 06:00 h). The temperature of the animal
room was  22 ± 1 ◦C, the relative humidity 40–70%, the illumina-
tion 120 lx. Animals had free access to water and were fed with an
amount of pellet food adequate to prevent excessive weight gain
(Voss et al., 2003). Handling and testing took place during the light
portion of the cycle.
2.2. Chemicals
The compounds used in the study were diazepam (Galenika,
Serbia) and the preferentially 1-subunit selective GABAA neutral
modulator CCt (t-butyl--carboline-3-carboxylate), synthesized
at the Department of Chemistry and Biochemistry, University of
Wisconsin-Milwaukee, USA. These compounds were suspended in
a solvent containing 85% distilled water, 14% propylene glycol, and
1% Tween 80, and were administered intraperitoneally (i.p.) in a
volume of 1 ml/kg. PTZ (Sigma–Aldrich Chemie GmbH, Germany)
was dissolved in physiological saline to prepare 40 mg/ml  concen-
tration for intravenous (i.v.) administration.
2.3. Experimental procedure
At the beginning of experiment, animals were randomly divided
into nine pretreatment groups. In order to ensure that all animals
passed through the same experimental procedure, rats were pro-
tractedly treated simultaneously with two  injections of solvent
(SOL–SOL), or 2 mg/kg diazepam and solvent (DZP–SOL), or 2 mg/kg
diazepam and 5 mg/kg CCt (DZP–CCt), intraperitoneally (i.p.),
once daily (at 8:30 h), during 14, 21 or 28 days. Approximately 24 h
after the last administration of treatment, animals were tested in
the elevated plus maze (EPM) test, followed by intravenous PTZ
infusion test.
2.4. EPM test
The EPM apparatus was constructed of sheet metal, with
a black rubber ﬂoor. It consisted of two  opposed open arms
(50 cm × 10 cm)  with ledges (0.3 cm high) and two opposed
enclosed arms (50 cm × 10 cm × 40 cm), connected by the junction
area (10 cm × 10 cm). The whole apparatus was elevated 50 cm
above the ﬂoor. Illumination in the experimental room was pro-
vided with one red neon tube ﬁxed on the ceiling above the maze.
Light intensity was  10 lx on the surface of the closed arms. Sin-
gle rats were placed in the center of the maze, facing one of the
enclosed arms and were allowed to freely explore the apparatus
during 5 min. The standard spatiotemporal variables were recorded
and analyzed using the ANY-maze Video Tracking System software
(Stoelting Co., Wood Dale, IL, USA) in accordance with our previ-
ous studies (Savic´ et al., 2004; Divljakovic´ et al., 2012). The primary
indices of anxiety were the percentage of open arm entries, the per-
centage of time spent on the open arms and time spent in the distal
parts of the open arms. The parameters related to motor activity
were the total distance traveled, number of total entries and closed
arm entries. An entry into an open arm, closed arm, or the distal part
of the open arm was  scored when 90% of animal crossed the virtual
line separating the neighboring zones, whereas an exit occurred
























































Fig. 1. The inﬂuence of withdrawal from protracted treatment for 14, 21 and 28
days with solvent (SOL–SOL), 2 mg/kg diazepam (DZP–SOL) and 2 mg/kg diazepam
with 5 mg/kg CCt (DZP–CCt) on the motor activity-related parameters in the EPM
test. Graphs (a)–(c) represent the effects of treatment and duration of treatment on
the total distance traveled, total arm entries and closed arm entries, respectively.
#P < 0.05 compared to 14 days of treatment, ∀ P < 0.05 compared to 28 days of treat-J. Kovacˇevic´ et al. / Brain R
hen more than 90% of animal left the respective zone. The distal
art of open arms was deﬁned as the area of the most distant 30%
f open arms.
.5. PTZ test
Immediately following EPM test, a single rat was placed in
he Plexiglas box (22 × 10 × 10 cm3) with holes for ventilation,
ithout strain. A butterﬂy infusion needle (needle size 25 G,
 in.) attached to a 20 ml  syringe preﬁlled with PTZ solution
as inserted into lateral tail vein. Correct placement was  veri-
ed by the appearance of blood in the infusion tubing. PTZ was
nfused at a constant rate of 0.5 ml/min using a motor driven infu-
ion pump (Stoelting Co., Wood Dale Illinois, USA). The volume
f solution infused before the appearance of full-blown clonic-
onic seizure was recorded (Fahey et al., 2006). The threshold
oses of PTZ (mg/kg) required to elicit seizures were calcu-
ated from the volume of infusion (ml), concentration of PTZ
mg/ml) and body weight (kg), using the following formula: vol-
me of PTZ (ml) × concentration of PTZ (mg/ml)/body weight
kg).
.6. Data analysis
All numerical data presented in the ﬁgures were given as the
ean ± SEM. Data obtained from the EPM test and PTZ test were
nalyzed using two-way ANOVA, with treatment and duration
f treatment as factors. If the ANOVA showed signiﬁcant effects
f factors or interaction (p < 0.05), post hoc Newman–Keuls test
as performed. Animals that fell from EPM apparatus and those
hich did not develop seizure due to improper cannulation of
he tail vein were omitted from data analysis. Statistical analyses
ere performed with ANY-maze software, where applicable, while




In regard to motor activity-related parameters (Fig. 1),
wo-way ANOVA revealed a signiﬁcant inﬂuence of factor dura-
ion of treatment on the total distance traveled (F(2,74) = 4.59,
 = 0.013), total arm entries (F(2,74) = 3.27, P = 0.044) and closed
rm entries (F(2,74) = 3.70, P = 0.030). The inﬂuences of factor
reatment and interaction between factors were not signiﬁcant
or these three parameters (total distance traveled: treatment
(2,74) = 2.64, P = 0.078 and interaction F(4,74) = 0.26; P = 0.903; total
rm entries: treatment F(2,74) = 2.40, P = 0.098 and interaction
(4,74) = 0.44, P = 0.781; closed arm entries: treatment F(2,74) = 3.08,
 = 0.052 and interaction F(4,74) = 0.18, P = 0.949). Post hoc test
evealed that rats protractedly treated for 21 days have shown
igniﬁcantly higher total distance traveled (Fig. 1a) than ani-
als protractedly treated during 14 and 28 days (P = 0.015 and
 = 0.020, respectively). The parameter total arm entries (Fig. 1b)
as higher for animals treated for 21 days than for those treated
or 28 days (P = 0.031); the closed arm entries (Fig. 1c) was higher
or groups treated for 21 days than for 14-days treated groups
P = 0.028).
Anxiety-related parameters are represented in Fig. 2. Two-way
NOVA did not reveal a signiﬁcant inﬂuence of factors treatment or
uration of treatment on any of the three parameters, namely the
ercentage of time on open arms (treatment F(2,74) = 0.76, P = 0.472
nd duration F(2,74) = 1.17, P = 0.316); the percentage of open arm
ntries (treatment F(2,74) = 0.84, P = 0.435 and duration F(2,74) = 1.70,
 = 0.190); and the time in distal part of open arms (treatmentment. Number of animals per group were: after 14 days of protracted treatment, 10,
10  and 7; after 21 days of treatment, 8, 9 and 10; after 28 days of treatment, 9, 10
and 10, for SOL–SOL, DZP–SOL and DZP–CCt groups, respectively.
F(2,74) = 0.17, P = 0.846 and duration F(2,74) = 2.90, P = 0.061). Inter-
action between factors was  signiﬁcant for the percentage of time
on open arms (F(4,74) = 3.13, P = 0.020, Fig. 2a), while it was  insigniﬁ-
cant for the percentage of open arm entries and time spent in distal
part of open arms (F(4,74) = 2.23, P = 0.074 and F(4,74) = 1.62, P = 0.179,
respectively; Fig. 2b and c). In regard to percentage of time on
open arms, post hoc test revealed that animals withdrawn from
protracted treatment with diazepam or diazepam and CCt for 28
days have shown signiﬁcantly lower percentage of time in open
arms than the group protractedly treated with solvent (P = 0.027
and P = 0.018, respectively).3.2. PTZ test
Results from PTZ test are represented in Fig. 3. Two-way ANOVA
revealed a signiﬁcant effect of factor treatment (F(2,63) = 12.01,
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Fig. 2. The inﬂuence of withdrawal from protracted treatment for 14, 21 and 28
days with solvent (SOL–SOL), 2 mg/kg diazepam (DZP–SOL) and 2 mg/kg diazepam
with 5 mg/kg CCt (DZP–CCt) on the anxiety-related parameters in the EPM test.





















Fig. 3. The inﬂuence of withdrawal from protracted treatment for 14, 21 and 28
days with solvent (SOL–SOL), 2 mg/kg diazepam (DZP–SOL) and 2 mg/kg diazepam
with 5 mg/kg CCt (DZP–CCt) on the threshold dose of PTZ in the PTZ infusion
test.  ** P < 0.01, *** P < 0.001 compared to respective SOL–SOL group,  P < 0.05, 
P  < 0.001 compared to DZP–CCt after 21 days. Number of animals per group were:
after  14 days of protracted treatment, 10, 8 and 7; after 21 days of treatment, 9, 8 andercentage of time on open arms, the percentage of open arm entries and time spent
n  distal part of open arms. * P < 0.05 compared to respective SOL–SOL group.
 < 0.001), whilst the inﬂuence of factor duration of treatment
as not signiﬁcant (F(2,63) = 2.58, P = 0.084). There was a signiﬁ-
ant interaction between factors (F(4,63) = 5.91, P < 0.001). After 14
ays of treatment, post hoc test did not reveal signiﬁcant differ-
nces in the threshold dose of PTZ between treatment groups.
n the other hand, withdrawal after 21 days of protracted treat-
ent with diazepam or diazepam and CCt led to signiﬁcant
ecrease of the threshold dose of PTZ, 24 h after the last treat-
ent injection (P < 0.001 for both treatments, compared to SOL–SOL
roup); the decrease of PTZ threshold dose was more prominent
or DZP–CCt group than for DZP–SOL (P = 0.040). Newman–Keuls
est also demonstrated a signiﬁcant decrease of the PTZ threshold
ose for DZP–SOL group in comparison with SOL–SOL group, 24 h
fter 28 days of treatment (P = 0.007). Finally, signiﬁcantly higher
oses of PTZ were needed to induce seizures 24 h after protracted
reatment with diazepam and CCt for 14 days and 28 days in com-
arison to the threshold dose needed after 21 days of the same
reatment (P < 0.001 and P = 0.015, respectively).7; and after 28 days of treatment, 8, 7 and 7, for SOL–SOL, DZP–SOL and DZP–CCt
groups, respectively.
4. Discussion
Development of physical dependence of benzodiazepine-type
drugs can be affected by the complex interaction between sev-
eral factors, such as the administered dose, dosing frequency, route
of administration and duration of chronic treatment (Ator and
Grifﬁths, 2003; Moser et al., 2011), which altogether govern recep-
tor exposure (Mirza and Nielsen, 2006). In this study we showed
that withdrawal of 2 mg/kg diazepam for 24 h after 28 days of pro-
tracted treatment led to an anxiety-like behavior in the EPM. An
increased susceptibility to PTZ-induced seizures was observed dur-
ing the diazepam withdrawal after 21 and 28 days of protracted
treatment. Antagonism of the diazepam effects at 1-containing
GABAA receptors throughout the protracted treatment, achieved
by co-administration of the neutral modulator CCt at a dose of
5 mg/kg, did not inﬂuence the anxiety level during withdrawal.
In regard to seizure susceptibility, protracted co-administration
of CCt with diazepam further decreased the PTZ-seizure thresh-
old after 21 days of treatment, whilst it prevented the diazepam
withdrawal-elicited decrease of the PTZ threshold after 28 days of
treatment.
Selective antagonism of the speciﬁc subtype of GABAA receptors,
as the innovative pharmacological approach in the investigations
of dependence liability, offers additional beneﬁts of time-limited
blockade during the chosen period of time, but is critically
dependent on the pharmacokinetic characteristics of the lig-
ands. For diazepam, elimination half-lives from plasma and brain
(18.24 ± 1.00 min  and 28.18 ± 6.70 min, respectively) obtained in
our unpublished study (Savic´ et al., unpublished data) have con-
ﬁrmed its fast elimination following a single i.p. dose in rats
(Friedman et al., 1986). Nevertheless, repeated administration
of diazepam once daily for 7 days can still result in signiﬁcant
accumulation of the parent molecule as well as the metabolite
N-methyldiazepam in rats (Fernandes et al., 1996). In accordance
with the suggested longer duration of action of CCt (Zhang et al.,
1995; June et al., 2003), its brain concentration of about 55 nmol/kg,
measured 16 h after the last dose in protracted (twice daily for 14
days) administration of CCt with diazepam (Savic´ et al., unpub-
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o prevent binding of diazepam at 1-containing GABAA receptors,
ithout affecting the withdrawal behavior. Finally, it is notewor-
hy that in the current study the compounds were dissolved in the
ame solvent as used in our previous behavioral and pharmacoki-
etic studies (Divljakovic´  et al., 2012, 2013; Savic´ et al., unpublished
ata).
In contrast to previous results (Izzo et al., 2001; Begg et al.,
005; dos Santos et al., 2010), the present study did not indi-
ate development of physical dependence after discontinuation
f diazepam treatment for 14 days. Namely, we  did not observe
ither an increased susceptibility to PTZ-induced seizures or an
ncreased level of anxiety 24 h after the last administration of
 mg/kg diazepam. As the present treatment schedule comprised
dministration of a relatively low diazepam dose, at low dosing
requency and by the route of administration characterized by fast
limination, the reason for the apparent discrepancy could be an
nsufﬁcient exposure to the drug. This ﬁnding supports the claims
n safety and efﬁcacy of benzodiazepines prescribed in low doses
or 1 or 2 weeks only, or intermittently (Ashton, 1994).
In the present EPM experiment, a stimulation of locomotion was
bserved for all groups treated for 21 days in comparison to the
roups treated for 14 and 28 days, indicating an adaptive behavioral
esponse to the environmental conditions and everyday handling
Costa et al., 2012; Schmitt and Hiemke, 1998). Such an adap-
ive behavioral response was not observed in our previous studies,
hen the protracted i.p. administration of treatment has been also
pplied (Divljakovic´ et al., 2012, 2013). The subtle differences in
he experimental design, such as co-administration of two  injec-
ions in the present, instead of one injection in previous studies,
ould have favored the development of the increased locomotion
fter 21 days of treatment. Noteworthy, the EPM test may  yield
 false positive anxiolytic-like effect when the procedure or treat-
ent increases locomotor activity (Dawson and Tricklebank, 1995).
ence, the detected hyperlocomotion could at least partly account
or the observed discordance between current results from the EPM
fter 21 days of treatment and our previous ﬁnding, when 24 h after
iscontinuation of the same diazepam treatment an anxiogenic-
ike response was observed (Divljakovic´ et al., 2013). Furthermore,
 trend of increase of the motor activity-related parameters (p < 0.1)
as more prominent for the group withdrawn from diazepam
reatment than for other two groups after 21 days of treatment.
rguably, this ﬁnding could be explained by a mild diazepam
ithdrawal-induced response, in a manner similar to the previ-
usly described with zolpidem (Elliot and White, 2000).
An overt anxiety-like response after diazepam withdrawal,
n the absence of signiﬁcant changes in motor activity, was
etected after 28 days of protracted treatment. Co-administration
f diazepam with CCt for 28 days did not change anxiety behav-
or during withdrawal, suggesting that protracted blockade of
1-containing GABAA receptors does not sufﬁce to prevent the
evelopment of an increased level of anxiety during diazepam
ithdrawal. However, acute challenge with CCt in a dose
ange from 1.25 to 20 mg/kg alleviated the anxiety induced
y abrupt cessation of protracted treatment with diazepam
Divljakovic´  et al., 2013). Taken together, these data suggest that
on-1GABAA receptors-mediated mechanisms are essential for
nduction of withdrawal-induced anxiety, whilst acute blockade of
1-containing GABAA receptors may  be sufﬁcient for reduction of
uch anxiety.
The PTZ test showed increased seizure susceptibility after
iazepam withdrawal after 21 days and 28 days of protracted treat-
ent. Our ﬁndings obtained after 21, but not 28 days of protractedreatment may  be seen as concordant with the hypothesis that ani-
als more sensitive to convulsions might be less prone to anxiety
Chapouthier and Venault, 2001). On the other hand, the present
tudy implies that the PTZ test is more sensitive and suitable inh Bulletin 104 (2014) 1–6 5
detecting effects of the benzodiazepine withdrawal than the EPM
test. It also suggests that results from PTZ test are not affected
by daily manipulation of animals. The ﬁnding that withdrawal
after 21 days of repeated co-administration of diazepam and CCt
has further increased susceptibility to the PTZ-induced seizures
may  mean that activation of 1-containing GABAA receptors dur-
ing protracted administration of diazepam exerts an alleviating
effect on development of increased seizure susceptibility dur-
ing withdrawal. However, this ﬁnding is in contrast with results
after 28 days of protracted treatment in the present study, when
antagonism of the effects mediated through the activation of 1-
containing GABAA receptors, achieved with co-administration of
diazepam and CCt, showed the ability to prevent the increased
seizure susceptibility during withdrawal.
The observed differences in the withdrawal effects after 21 and
28 days of protracted treatment, as well as differences between
ﬁndings from EPM and PTZ test could be the consequence of
differential adaptive changes in the neuroanatomical circuits, as
suggested by Pratt et al. (1998). Furthermore, the differential
involvement of 1-containing GABAA receptors in the mechanisms
underlying benzodiazepine physical dependence could be hypoth-
esized from conﬂicting ﬁndings with zolpidem, the preferentially
1- selective positive allosteric modulator of GABAA receptors
(Sanna et al., 2002). Namely, the decreased dependence liability
of zolpidem after protracted treatment in mice (Elliot and White,
2000; Mirza and Nielsen, 2006; Perrault et al., 1992) supports
our data from the EPM test after 28 days and PTZ test after 21
days, and points to the role of non-1-containing GABAA receptors
in the development of physical dependence, or even an allevi-
ating effect of the activation of 1-containing GABAA receptors
in this process. On the other hand, ﬁndings of withdrawal syn-
drome after discontinuation of zolpidem in primates (Weerts et al.,
1998), but also in mice (Wright et al., 2014), support our data from
PTZ test after 28 days, suggesting that activation of 1-containing
GABAA receptors is necessary for development of phenomena
related with protracted administration of benzodiazepines. Taken
together, antagonism at 1-containing GABAA receptors is probably
insufﬁcient for consistent prevention of the development of phys-
ical dependence, while 1-sparing ligands coupled with reduced
activity at non-1-containing GABAA receptors might be candi-
dates suitable for long-term therapy (Ator et al., 2010; Mirza and
Nielsen, 2006).
In conclusion, the current study suggests that the role of
predominant 1-containing GABAA receptors in mediating devel-
opment of physical dependence relates to the observed effect and
duration of protracted benzodiazepine treatment. Hence, it may  be
not possible to identify one particular subtype of GABAA receptors
as being responsible for the development and expression of phys-
ical dependence, and further efforts aimed at developing ligands
devoid of physical dependence liability should be pointed toward
reduction of activity at non-1-containing GABAA receptors.
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